Emcure Pharmaceuticals Limited — Board Meeting, 07-08-2025: Outcome of Board Meeting

Emcure Pharmaceuticals' Board has approved robust Q1FY26 consolidated financial results. Revenue soared 15.7% YoY to Rs 2,101 Cr, and Profit After Tax (PAT) surged 41% to Rs 215 Cr. EBITDA grew 20.1% to Rs 404 Cr, with margins at 19.2%. Domestic sales rose 9.4% to Rs 995 Cr, while International sales jumped 22.1% to Rs 1,106 Cr. Key strategic updates include subsidiary Tillomed's Rs 220.25 Cr acquisition of Manx Healthcare's product portfolio and plans to make Zuventus Healthcare a wholly-owned subsidiary. Emcure also expanded its Sanofi partnership.